Biotechnology group listed on BME MAB (BST). Holder of Splittera platform and technologies for gene therapy, CAR-T and vaccines. GLP-certified zebrafish CRO services (ENAC 2026).
Biat Group - Biotecnología andaluza cotizada en BME MAB · Ticker BSTOct 2026
ZIP Solutions, a subsidiary of BIAT Group (BME ticker BST), has recently published in Frontiers in Immunology a study providing an in vitro proof of concept for Click-CAR development. The design aims to build chimeric antigen receptors (CARs) from separate modules, exploring new ways to regulate cell therapy activity.
Biat Group - Biotecnología andaluza cotizada en BME MAB · Ticker BSTSep 2026
Biobide, the San Sebastián-headquartered CRO with a US office in Cambridge, MA and part of BIAT Group (BME Growth: BST), has expanded its ecotoxicology offering into a full-spectrum battery covering every level of the ecosystem.
Biat Group - Biotecnología andaluza cotizada en BME MAB · Ticker BSTJul 2026
A study published in NeuroToxicology supports the zebrafish Light–Dark Transition Test (LDTT) as a reliable early screening tool for developmental neurotoxicity, strengthening its potential role in emerging regulatory testing strategies.
Biat Group - Biotecnología andaluza cotizada en BME MAB · Ticker BSTJul 2026
Biobide’s aquatic toxicity data will also be available through AsedaSciences’ AI 3RnD platform into an environment alongside study ordering, visualization, and analysis.
Biat Group - Biotecnología andaluza cotizada en BME MAB · Ticker BSTJul 2026
A study led by NIEHS/NIH, with participation from Biobide, the US-EPA, the University of Konstanz, and the IUF-Leibniz Institute, published in the journal Neurotoxicology, validates and proposes a test battery for the detection of developmental neurotoxicity that includes Biobide’s zebrafish DNT assay.